Mets Pitcher Jenrry Mejia Fails Third Drug Test, Receives Lifetime Baseball Ban

  • by: Perry Sanders III


Mets reliever Jenrry Mejia from Major League Baseball has been permanently banned from MLB after testing positive for performance-enhancing drugs for the third time.

Mejia, 26, tested positive for Boldenone, an old-school type anabolic steroid.

The stud pitcher was suspended for 50 games at the beginning of last season after his first failed test. After returning from his suspension, Mejia played seven games in July before flunking for a second time, earning a 162-game ban that would have carried over into the 2016 season.

Mejia is allowed to apply for reinstatement from the lifetime ban in one year, but must miss a minimum of two years.

He had his best season in 2014, when struck out 98 batters in 93 2/3 innings.

Lead Stories' Trendolizerβ„’ is constantly scouring the web for the hottest news, viral videos and images.

Follow us on Facebook and Twitter @LeadStoriesCom for your daily news.

Thumbnail image for p3.jpgPerry Sanders III is a Philosophy graduate of the University of Colorado at Colorado Springs, and is an editor and social media manager at Lead Stories.

Read more about or contact

About us

International Fact-Checking Organization Meta Third-Party Fact Checker

Lead Stories is a U.S. based fact checking website that is always looking for the latest false, misleading, deceptive or inaccurate stories, videos or images going viral on the internet.
Spotted something? Let us know!.

Lead Stories is a:

Follow us on social media

Subscribe to our newsletter

* indicates required

Please select all the ways you would like to hear from Lead Stories LLC:

You can unsubscribe at any time by clicking the link in the footer of our emails. For information about our privacy practices, please visit our website.

We use Mailchimp as our marketing platform. By clicking below to subscribe, you acknowledge that your information will be transferred to Mailchimp for processing. Learn more about Mailchimp's privacy practices here.

Most Read

Most Recent

Share your opinion